Regulatory approval
Published by the Health Service Executive. Approved
The Republic of Ireland's Health Service Executive (HSE) has approved idelalisib in combination with rituximab for reimbursement as a treatment option for the first-line treatment of adult patients with chronic lymphocytic leukemia (CLL) who are not eligible for any other therapies and whose tumors have 17p deletion or TP53 mutated disease.
This is written in the approval document as:
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.
Reimbursement
Hybrid
Idelalisib - CDS; riTUXimab - Hospital
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| HSE (1) | TP53 Somatic variants | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab | |
| HSE (1) | 17p deletion | Chronic Lymphocytic Leukemia | Idelalisib, Rituximab |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |
| 2017-01-05 | Health Service Executive | Indication approved for reimbursement. |